Pediatric brain tumor can be defined as an unnatural growth of a normal cell inside the brain of a children. These tumors are of two types cancerous (malignant) and noncancerous (benign). The type is quite common in children. Governments are putting in great effort to counter this type of disease, which is giving substantial traction to the global pediatric brain tumor market. The market can achieve a growth by 4.1% CAGR during the forecast period to surpass USD 1659.4 million worth mark during the forecast period of 2018 to 2023.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/3690
Factors like heightened medical facilities, inclusion of top-class medical equipment, better government initiative, high investment from both private and government sectors, concerns shown by research & development sector, better insurance coverage, and others can inspire the global pediatric brain tumor market growth in the coming years.
A better understanding of the global pediatric brain tumor market can be segmented on the basis of types, diagnosis, and treatment.
By type, the global pediatric brain tumor market can be segmented into mixed neuronal-glial tumors, gliomas, choroid plexus papilloma/carcinoma, embryonal tumors, meningeal tumors, tumors arising from non-neuroepithelial tissue, and others. The gliomas segment includes malignant gliomas, astrocytoma, and others. Mixed neuronal-glial tumors are segmented into pleomorphic xanthoastrocytoma, subependymal giant cell tumor, ganglioglioma, and others. Embryonal tumors segment encompasses primitive neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor, and others. Tumors arising from non-neuroepithelial tissue includes pineal region tumors, craniopharyngioma, and others.
Based on the diagnosis, the global pediatric brain tumor market can be segmented into physical exam, Imaging tests, lumbar puncture (spinal tap), brain or spinal cord tumor biopsy, blood & urine tests, and others. Imaging tests includes Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI) scan, Angiogram, Positron Emission Tomography (PET) scan, and others. Magnetic Resonance Imaging (MRI) scan comprises Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Angiography (MRA), Functional MRI (fMRI), Magnetic Resonance Perfusion, and others. Brain or spinal cord tumor biopsy can be studied better on the basis of craniotomy, stereotactic needle biopsy, and other.
By treatment, the pediatric brain tumor market has been studied on the basis of therapies, surgery, drug treatment, and others. Surgery segment includes resection (removal), shunt placement/revision, surgical biopsy, and others. Therapies segment has been studied with focus on chemotherapy, radiation therapy, targeted therapy, and others. Chemotherapy segment covers carboplatin, cisplatin, carmustine (BCNU), vincristine, etoposide, cyclophosphamide, methotrexate, lomustine (CCNU), thiotepa, temozolomide, and others. Drug treatment segment includes hormones, corticosteroids, anti-seizure drugs (anti-epileptics), and others.
By end user, the pediatric brain tumor market consists hospitals & clinics, medical research centers, academic institutes, and others.
By considering the pediatric brain tumor market on a region-specific level, MRFR included regions like North America, Europe, Asia Pacific (APAC), and the Rest-of-the-World (RoW). These segments are expected to thrive on various demographic features that can be studied to increase the profit margin in the coming years.
North America has the better market coverage and it can grow in the coming years with strong contributions made by the US and Canada. This is due to high level of awareness better market percolation of various industries, hike in healthcare expenditure, and various other factors. Europe is also in the line to earn revenues. The regional healthcare sector has similar market benefits like that of North America. In the APAC region, the market can depend on revamping healthcare sector, which can fetch in better revenues for the market.
The global pediatric brain tumor market is all set to gain from the participation of several top-notch players. These companies are expected to launch their own strategic moves to ensure easy stay in the global market. Their tactical moves are expected to include merger, innovation, collaboration, branding, and others. MRFR enlisted these companies for a better understanding of the market in the coming days. These companies are AbbVie Inc. (US), Abbott. (US), Agios, Inc. (US), Akorn, Inc. (US), Bayer AG (US), Baxter (US), Novartis AG (Switzerland), Epizyme, Inc. (US), Mylan N.V. (US), and others.
In August 2019, Moleculin Biotech announced their move forward with the new WP1066 that has recently got a clean chit from FDAs. The medicine, as per the market analysts would help the global presence of the Moleculin Biotech in stepping forward.
Browse Premium Research Report with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/pediatric-brain-tumor-market-3690
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312